The programmed death-ligand 1 directed antibody atezolizumab confers an overall survival advantage relative to docetaxel in previously treated patients with locally advanced or metastatic non-small-cell lung cancer, indicate phase III trial findings.
Updated phase III trial results show that ipilimumab treatment improves overall survival and distant metastasis-free survival in stage III melanoma patients who have undergone complete resection, but with increased toxicity relative to placebo.
Follow-up results from two trials of the programmed death 1 receptor inhibitor nivolumab versus docetaxel in patients with advanced non-small cell lung cancer were reported at a proffered paper session held at the European Cancer Congress in Vienna, Austria.
Results from early phase trials investigating different therapeutic agents in lung cancer patients were presented during the third Presidential Session at the European Cancer Congress in Vienna, Austria. Here we summarise two studies reported at the session.
The safety and efficacy of the programmed death 1 inhibitors nivolumab and pembrolizumab in patients with melanoma formed a key part of the Melanoma and Skin Cancer proffered paper session at the European Cancer Congress in Vienna, Austria. This report summarises two presentations from the session.
Updated results from the COMBI-v trial show significantly improved overall and progression-free survival with first-line dabrafenib plus trametinib compared with vemurafenib in patients with advanced melanoma.
Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.
Subgroups of advanced melanoma patients with a poor prognosis derive a progression-free survival benefit from the combination of nivolumab and ipilimumab, according to research presented at the European Cancer Congress in Vienna, Austria.
Two phase III trials published in The New England Journal of Medicine support the use of nivolumab in patients with treatment-naïve metastatic melanoma and in those with squamous non-small-cell lung cancer who have failed first-line chemotherapy.
The addition of ibrutinib to bendamustine and rituximab significantly prolongs progression-free survival in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma, according to the HELIOS trial.
Addition of the immunostimulatory antibody elotuzumab to the combination of lenalidomide and dexamethasone improves progression-free survival and the overall response rate in patients with relapsed or refractory multiple myeloma, research suggests.